Geode Capital Management
MLTX icon

Geode Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Geode Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Buy
74,760
+2,491
+3% +$45.2K ﹤0.01% 3264
2026
Q1 		$1.35M Sell
72,269
-337
-0.5% -$5.58K ﹤0.01% 3264
2025
Q4 		$956K Buy
72,606
+10,221
+16% +$121K ﹤0.01% 3394
2025
Q3 		$447K Buy
62,385
+2,832
+5% +$148K ﹤0.01% 3661
2025
Q2 		$2.81M Buy
59,553
+559
+0.9% +$22.8K ﹤0.01% 3025
2025
Q1 		$2.3M Buy
58,994
+44
+0.1% +$1.9K ﹤0.01% 2984
2024
Q4 		$3.19M Buy
58,950
+540
+0.9% +$27.6K ﹤0.01% 2955
2024
Q3 		$2.95M Sell
58,410
-90
-0.2% -$4.22K ﹤0.01% 3004
2024
Q2 		$2.57M Buy
58,500
+4,474
+8% +$190K ﹤0.01% 3046
2024
Q1 		$2.71M Buy
54,026
+5,252
+11% +$285K ﹤0.01% 2995
2023
Q4 		$2.95M Buy
48,774
+4,966
+11% +$256K ﹤0.01% 2962
2023
Q3 		$2.5M Buy
43,808
+11,840
+37% +$654K ﹤0.01% 2992
2023
Q2 		$1.63M Buy
31,968
+14,859
+87% +$400K ﹤0.01% 3175
2023
Q1 		$366K Buy
17,109
+5,658
+49% +$95.1K ﹤0.01% 3774
2022
Q4 		$120K Buy
+11,451
New +$102K ﹤0.01% 4327

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management's MLTX Position: Q2 2026 in Review

Geode Capital Management increased its MoonLake Immunotherapeutics (MLTX) stake by 3.4% in Q2 2026, buying an estimated $45.2K and bringing the position to 74,760 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #3264.

Geode Capital Management first reported a position in MLTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.19M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Geode Capital Management held 74,760 shares of MoonLake Immunotherapeutics worth $1.45M as of Q2 2026.
  • Geode Capital Management bought 2,491 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $45.2K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3264 holding.
  • Geode Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 15 quarters since.
  • Geode Capital Management's MoonLake Immunotherapeutics position peaked at $3.19M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.